No Data
Sinolink: Focus on innovative growth in pharmaceutical investment for 2025, with a dual approach of "AI + Innovative Drugs."
In traditional medicine, policy expectations are anticipated to reverse and performance pressure may soon show a turnaround. Seize the opportunities of Innovative Drugs expanding overseas and the increased volume in the domestic market, as well as the recovery opportunities in the left-side Sector stocks.
With 51% Ownership, Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) Insiders Have a Lot at Stake
Sinolink: The rising enthusiasm for HEALTH CARE A applications is worth investing in; the traditional main line may welcome a reversal in the quarterly reports.
With the development and progress of AI technology, AI continuously makes new advancements in empowering medical and healthcare, promoting industry upgrades, and its application in the medical and health field is expected to enter an accelerated development stage.
Xiamen Amoytop Biotech's (SHSE:688278) 44% CAGR Outpaced the Company's Earnings Growth Over the Same Three-year Period
Xiamen Amoytop Biotech's Electronic Pen Injector Gets Registration Certificate From China's Fujian Province
Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.
In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.
Here's Why We Think Xiamen Amoytop Biotech (SHSE:688278) Might Deserve Your Attention Today